New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice . Image Credit: Pixel-Shot / Shutterstock.
com A recent JAMA Network Open study compares the weight loss efficacy of injectable liraglutide and semaglutide, in addition to identifying the factors associated with a weight reduction of 10% or more after one year of treatment. Treating obesity Obesity leads to or worsens the risk of various health disorders, some of which include cardiovascular disease, cancer, type 2 diabetes (T2D), osteoarthritis, and obstructive sleep apnea. Over the past two decades, the United States Food and Drug Administration (FDA) has approved two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treating obesity, of which include liraglutide and semaglutide.
In randomized clinical trials, liraglutide and semaglutide have led to significant weight reductions. However, outside of clinical trials, weight loss data with liraglutide or semaglutide has been limited to a short follow-up period of six months. About the study In the present study, weight outcomes among obese patients who received injectable forms of semaglutide or liraglutide at one year were assessed between January 1, 2015, and July 28, 2023.
Outcomes were compared by GLP-1 RA agent, dosage, indication, and persistent coverage with the .